Ursolic acid enhances the antitumor effects of sorafenib associated with Mcl-1-related apoptosis and SLC7A11-dependent ferroptosis in human cancer
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Ursolic acid enhances the antitumor effects of sorafenib associated with Mcl-1-related apoptosis and SLC7A11-dependent ferroptosis in human cancer
Authors
Keywords
-
Journal
PHARMACOLOGICAL RESEARCH
Volume 182, Issue -, Pages 106306
Publisher
Elsevier BV
Online
2022-06-15
DOI
10.1016/j.phrs.2022.106306
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Broadening horizons: the role of ferroptosis in cancer
- (2021) Xin Chen et al. Nature Reviews Clinical Oncology
- Targeting MCL-1 in cancer: current status and perspectives
- (2021) Haolan Wang et al. Journal of Hematology & Oncology
- Unsaturated fatty acids as a co-therapeutic agents in cancer treatment
- (2021) Zahra Asefy et al. MOLECULAR BIOLOGY REPORTS
- Cell Death in the Origin and Treatment of Cancer
- (2020) Andreas Strasser et al. MOLECULAR CELL
- Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy
- (2020) Pranavi Koppula et al. Protein & Cell
- Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins
- (2019) Rumani Singh et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Molecular Comprehension of Mcl-1: From Gene Structure to Cancer Therapy
- (2019) Viacheslav V. Senichkin et al. TRENDS IN CELL BIOLOGY
- Overriding adaptive resistance to sorafenib via combination therapy with SHP2 blockade in hepatocellular carcinoma
- (2019) Carmen Oi Ning Leung et al. HEPATOLOGY
- Recent developments on the extraction and application of ursolic acid. A review
- (2018) Lucía López-Hortas et al. FOOD RESEARCH INTERNATIONAL
- Combination therapy with protein kinase inhibitor H89 and Tetrandrine elicits enhanced synergistic antitumor efficacy
- (2018) Man Yu et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- phospho-ERK is a biomarker of response to a synthetic lethal drug combination of sorafenib and MEK inhibition in liver cancer
- (2018) Cun Wang et al. JOURNAL OF HEPATOLOGY
- Omega-3 fatty acids, membrane remodeling and cancer prevention
- (2018) Natividad R. Fuentes et al. MOLECULAR ASPECTS OF MEDICINE
- Arsenic trioxide and sorafenib induce synthetic lethality of FLT3-ITD acute myeloid leukemia cells
- (2018) Rui Wang et al. MOLECULAR CANCER THERAPEUTICS
- c-MYC and reactive oxygen species play roles in tetrandrine-induced leukemia differentiation
- (2018) Guixian Wu et al. Cell Death & Disease
- The role of cellular reactive oxygen species in cancer chemotherapy
- (2018) Haotian Yang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Reversal of multidrug resistance in breast cancer cells by a combination of ursolic acid with doxorubicin
- (2018) Li Zong et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- Ursolic acid derivatives for pharmaceutical use: a patent review (2012-2016)
- (2017) Hidayat Hussain et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Phase II Trial of Sorafenib in Combination with Capecitabine in Patients with Hepatocellular Carcinoma: INST 08‐20
- (2017) Yehuda Patt et al. ONCOLOGIST
- Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma – The SHELTER study
- (2016) Michael Bitzer et al. JOURNAL OF HEPATOLOGY
- Ursolic acid (UA): A metabolite with promising therapeutic potential
- (2016) Dharambir Kashyap et al. LIFE SCIENCES
- Ferroptosis: Death by Lipid Peroxidation
- (2016) Wan Seok Yang et al. TRENDS IN CELL BIOLOGY
- Ursolic acid sensitizes cisplatin-resistant HepG2/DDP cells to cisplatin via inhibiting Nrf2/ARE pathway
- (2016) Shouhai Wu et al. Drug Design Development and Therapy
- Ursolic acid synergistically enhances the therapeutic effects of oxaliplatin in colorectal cancer
- (2016) Jianzhen Shan et al. Protein & Cell
- Tetrandrine is a potent cell autophagy agonist via activated intracellular reactive oxygen species
- (2015) Haiqing Wang et al. Cell and Bioscience
- Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer
- (2015) Yelena Y. Janjigian et al. PLoS One
- ABT-263 enhances sorafenib-induced apoptosis associated with Akt activity and the expression of Bax and p21(CIP1/WAF1)in human cancer cells
- (2014) Jingru Li et al. BRITISH JOURNAL OF PHARMACOLOGY
- HCC—subtypes, stratification and sorafenib
- (2014) Gregory J. Gores Nature Reviews Gastroenterology & Hepatology
- Ursolic acid in cancer prevention and treatment: Molecular targets, pharmacokinetics and clinical studies
- (2013) Muthu K. Shanmugam et al. BIOCHEMICAL PHARMACOLOGY
- Synergistic antitumour activity of sorafenib in combination with tetrandrine is mediated by reactive oxygen species (ROS)/Akt signaling
- (2013) J Wan et al. BRITISH JOURNAL OF CANCER
- Sensitization of ionizing radiation-induced apoptosis by ursolic acid
- (2012) Su Jin Koh et al. FREE RADICAL RESEARCH
- Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update
- (2012) Angela Gauthier et al. HEPATOLOGY RESEARCH
- Autophagy-related Gene 7 (ATG7) and Reactive Oxygen Species/Extracellular Signal-regulated Kinase Regulate Tetrandrine-induced Autophagy in Human Hepatocellular Carcinoma
- (2012) Ke Gong et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Doxorubicin Plus Sorafenib vs Doxorubicin Alone in Patients With Advanced Hepatocellular Carcinoma
- (2010) Ghassan K. Abou-Alfa et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation
- (2009) S. Metzelder et al. BLOOD
- Phase II, Multicenter, Uncontrolled Trial of Single-Agent Sorafenib in Patients With Relapsed or Refractory, Advanced Non–Small-Cell Lung Cancer
- (2009) George R. Blumenschein et al. JOURNAL OF CLINICAL ONCOLOGY
- Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
- (2008) Scott M. Wilhelm et al. MOLECULAR CANCER THERAPEUTICS
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now